Zobrazeno 1 - 10
of 593
pro vyhledávání: '"McLean LR"'
Autor:
Frenzel, Katja1 (AUTHOR) katja.frenzel@ptb.de, Kayser, Yves1 (AUTHOR), Hornemann, Andrea2 (AUTHOR), Kästner, Bernd1 (AUTHOR), Hoehl, Arne1 (AUTHOR), Mouratidis, Petros2 (AUTHOR), Rivens, Ian2 (AUTHOR), ter Haar, Gail2 (AUTHOR), Beckhoff, Burkhard1 (AUTHOR)
Publikováno v:
PLoS ONE. 9/4/2024, Vol. 19 Issue 9, p1-23. 23p.
Autor:
Vaz RJ; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA. Electronic address: roy.vaz@sanofi.com., Li Y; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Chellaraj V; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Reiling S; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Kuntzweiler T; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Yang D; Pre-Development Sciences, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Shen H; Pre-Development Sciences, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Batchelor JD; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Zhang Y; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Chen X; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., McLean LR; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA., Kosley R Jr; Integrated Drug Discovery, Sanofi US, 153-2nd Ave., Waltham, MA 02451, USA.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Oct 15; Vol. 28 (19), pp. 3194-3196. Date of Electronic Publication: 2018 Aug 20.
Autor:
Kim, Jeongeun1 (AUTHOR), Kim, Jueun1,2 (AUTHOR), Yun, Hyosuk1 (AUTHOR), Ganbaatar, Byambasuren1 (AUTHOR), Tahmasebi, Aminallah1,3 (AUTHOR), Seo, Sun Il4 (AUTHOR), Kim, Pyoung Il4 (AUTHOR), Lee, Chul Won1 (AUTHOR) cwlee@jnu.ac.kr
Publikováno v:
PLoS ONE. 4/1/2024, Vol. 19 Issue 4, p1-23. 23p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Deng G; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139, gejing.deng@sanofi.com., Shen J; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Yin M; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., McManus J; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Mathieu M; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Gee P; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., He T; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Shi C; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Bedel O; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., McLean LR; Division of Lead Generation & Compound Realization, Sanofi, Waltham, Massachusetts 02452, and., Le-Strat F; Department of Disposition, Safety & Animal Research, Sanofi, Chilly-Mazarin 91385, France., Zhang Y; Division of Lead Generation & Compound Realization, Sanofi, Waltham, Massachusetts 02452, and., Marquette JP; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Gao Q; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Zhang B; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Rak A; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Hoffmann D; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Rooney E; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Vassort A; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Englaro W; Division of Lead Generation & Compound Realization, Sanofi, Vitry 94403, France., Li Y; Division of Lead Generation & Compound Realization, Sanofi, Waltham, Massachusetts 02452, and., Patel V; Division of Lead Generation & Compound Realization, Sanofi, Waltham, Massachusetts 02452, and., Adrian F; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Gross S; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Wiederschain D; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Cheng H; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139., Licht S; From Division of Oncology Drug Discovery and Preclinical Development, Sanofi, Cambridge, Massachusetts 02139.
Publikováno v:
The Journal of biological chemistry [J Biol Chem] 2015 Jan 09; Vol. 290 (2), pp. 762-74. Date of Electronic Publication: 2014 Nov 12.
Autor:
Lin, Chenglong1,2,3 (AUTHOR), Li, Yanyan1,2,3 (AUTHOR), Peng, Yusi1,2,3 (AUTHOR), Zhao, Shuai1,2,3 (AUTHOR), Xu, Meimei1,2,3 (AUTHOR), Zhang, Lingxia1,3 (AUTHOR), Huang, Zhengren1,3 (AUTHOR) zhrhuang@mail.sic.ac.cn, Shi, Jianlin1,3 (AUTHOR), Yang, Yong1,3 (AUTHOR) yangyong@mail.sic.ac.cn
Publikováno v:
Journal of Nanobiotechnology. 5/6/2023, Vol. 21 Issue 1, p1-37. 37p.
Autor:
McLean LR; Molecular Innovative Therapeutics, Sanofi US, 1041 Route 202/206 N, Bridgewater, NJ 08807, United States. Larry.McLean@sanofi.com, Zhang Y, Zaidi N, Bi X, Wang R, Dharanipragada R, Jurcak JG, Gillespy TA, Zhao Z, Musick KY, Choi YM, Barrague M, Peppard J, Smicker M, Duguid M, Parkar A, Fordham J, Kominos D
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 May 01; Vol. 22 (9), pp. 3296-300. Date of Electronic Publication: 2012 Mar 11.
Autor:
Liang G; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Chen X; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Aldous S; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Pu SF; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Mehdi S; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Powers E; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Giovanni A; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Kongsamut S; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Xia T; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Zhang Y; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Wang R; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Gao Z; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Merriman G; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., McLean LR; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States., Morize I; Molecular Innovative Therapeutics, Fibrosis and Wound Repair, Global Pharmacovigilance & Epidemiology, Immunology and Inflammation Unit, Early to Candidate Unit, Aging Therapeutic Unit, and Biologics, Sanofi Pharmaceuticals , 1041 Route 202/206, Mailstop 203A, Bridgewater, New Jersey 08807, United States.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2012 Jan 11; Vol. 3 (2), pp. 159-64. Date of Electronic Publication: 2012 Jan 11 (Print Publication: 2012).
Autor:
McLean LR; Discovery Research, Sanofi-aventis, Bridgewater, NJ 08807, USA. Larry.Mclean@sanofi-aventis.com, Zhang Y, Li H, Choi YM, Han Z, Vaz RJ, Li Y
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2010 Mar 15; Vol. 20 (6), pp. 1821-4. Date of Electronic Publication: 2010 Feb 06.
Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
Autor:
McLean LR; Discovery Research, Sanofi-aventis, Bridgewater, NJ 08807, USA. Larry.Mclean@sanofi-aventis.com, Zhang Y, Degnen W, Peppard J, Cabel D, Zou C, Tsay JT, Subramaniam A, Vaz RJ, Li Y
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2010 Mar 15; Vol. 20 (6), pp. 1981-4. Date of Electronic Publication: 2010 Jan 25.